To explore the use of GALV-RRV for prodrug activator gene therapy of glioma, in these studies we used an immune-competent rodent model of intracerebral glioma to examine tumor growth as well as survival after intracerebral inoculation of GALV-RRV carrying CD and NTR genes, followed by treatment with their respective prodrugs. This evidence concerns the gene NTSR1 and neoplasm.